

PubMed

Format: Abstract

Eur Urol Focus. 2019 Jun 24. pii: S2405-4569(19)30159-2. doi: 10.1016/j.euf.2019.06.004. [Epub ahead of print]

Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations.

Van den Broeck T¹, van den Bergh RCN², Briers E³, Cornford P⁴, Cumberbatch M⁵, Tilki D⁶, De Santis M⁷, Fanti S⁸, Fossati N⁹, Gillessen S¹⁰, Grummet JP¹¹, Henry AM¹², Lardas M¹³, Liew M¹⁴, Mason M¹⁵, Moris L¹⁶, Schoots IG¹⁷, van der Kwast T¹⁸, van der Poel H¹⁹, Wiegel T²⁰, Willemse PM²¹, Rouvière O²², Lam TB²³, Mottet N²⁴.

Author information

Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) based on disease and prostate-specific antigen characteristics. **PATIENT SUMMARY:** Following treatment to cure prostate cancer, some patients can develop recurrence of disease identified via a prostate-specific antigen blood test (ie, biochemical recurrence, or BCR). However, not every man who experiences BCR develops progressive disease (symptoms or evidence of disease progression on imaging). We conducted a review of the literature and developed a classification system for predicting which patients might progress to optimize treatment decisions.

Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

KEYWORDS: Biochemical recurrence; European Association of Urology; Gleason score; Guidelines; PSA kinetics; Prognostic factors; Prostate cancer; Radical prostatectomy; Radiotherapy

PMID: 31248850 DOI: [10.1016/j.euf.2019.06.004](https://doi.org/10.1016/j.euf.2019.06.004)